The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB

References

• Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410–1416.
   Google Scholar
• Troch M, Woehrer S, Streubel B, et al. Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. Ann Oncol 2008;19:1336–1339.
   PubMed Web of Science ®Google Scholar
• Wöhrer S, Troch M, Streubel B, et al. Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. Ann Oncol 2007;18:2020–2024.
   PubMed Web of Science ®Google Scholar
• Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23: 6370–6378.
   PubMed Web of Science ®Google Scholar
• Streubel B, Simonitsch-Klupp I, Müllauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004;18:1722–1726.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420–430.
   PubMed Web of Science ®Google Scholar
• Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000;407:810–816.
   PubMed Web of Science ®Google Scholar
• Bucur O, Ray S, Bucur MC, et al. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 2006;11:68.
   Web of Science ®Google Scholar
• O’Kane HF, Watson CJ, Johnston SR, et al. Targeting death receptors in bladder, prostate and renal cancer. J Urol 2006;175:432–438.
   PubMed Web of Science ®Google Scholar
• Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 2008;8:37–46.
   PubMed Web of Science ®Google Scholar
• Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479–489.
   PubMed Web of Science ®Google Scholar
• Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481–490.
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009;127:145–154.
   PubMed Web of Science ®Google Scholar
• Zamai L, Ahmad M, Bennett IM, et al. Natural killer (NK) cell–mediated cytotoxicity:differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998;188:2375–2380.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance:immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715–727.
   PubMed Web of Science ®Google Scholar
• Baritaki S, Katsman A, Chatterjee D, et al. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol 2007;179:5441–5453.
   PubMed Web of Science ®Google Scholar
• Medema J, De Jong J, Peltenburg L, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001;98:11515–11520.
   PubMed Web of Science ®Google Scholar
• Ochsenbein AF. Immunological ignorance of solid tumors. Springer Semin Immunopathol 2005;27:19–35.
   PubMed Web of Science ®Google Scholar
• Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor–related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005;3:335–343.
   PubMed Web of Science ®Google Scholar
• Horak P, Pils D, Kaider A, et al. Perturbation of the tumor necrosis factor–related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 2005;11: 8585–8591.
   PubMed Web of Science ®Google Scholar
• Anees M, Horak P, El‐Gazzar A, et al. Recurrence‐free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 2011;117:1172–1182.
   PubMed Web of Science ®Google Scholar
• Jourdan M, Rème T, Goldschmidt H, et al. Gene expression of anti‐and pro‐apoptotic proteins in malignant and normal plasma cells. Br J Hematol 2009;145:45–58.
   PubMed Web of Science ®Google Scholar
• Lincz L, Yeh T, Spencer A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001;15:1650–1657.
   PubMed Web of Science ®Google Scholar
• Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, et al. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007;313:2378–2388.
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL AND TNF-α in human multiple myeloma cells is not blocked by BCL-2. Cytokine 1999;11:1010–1019.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma:therapeutic applications. Blood 2001;98: 795–804.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525–4530.
   PubMed Web of Science ®Google Scholar
• Inagaki H, Okabe M, Seto M, et al. API2-MALT1 fusion transcripts involved in mucosa-associated lymphoid tissue lymphoma: multiplex RT-PCR detection using formalin-fixed paraffin-embedded specimens. Am J Pathol 2001;158:699–706.
   PubMed Web of Science ®Google Scholar
• Ye H, Liu H, Attygalle A, et al. Variable frequencies of t (11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003;102:1012–1018.
   PubMed Web of Science ®Google Scholar
• Seo SI, Song SY, Kang MR, et al. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers. APMIS 2009;117:623–628.
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813–820.
   PubMed Web of Science ®Google Scholar
• Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling:a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010;42:210–213.
   PubMed Web of Science ®Google Scholar
• Krueger A, Schmitz I, Baumann S, et al. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 2001;276:20633.
   PubMed Web of Science ®Google Scholar
• Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190–194.
   PubMed Web of Science ®Google Scholar
• Shu HB, Halpin DR, Goeddel DV. Casper is a FADD-and caspase-related inducer of apoptosis. Immunity 1997;6:751–763.
   PubMed Web of Science ®Google Scholar
• Zhang N, He YW. An essential role for c-FLIP in the efficient development of mature T lymphocytes. J Exp Med 2005;202: 395–404.
   PubMed Web of Science ®Google Scholar
• Zhang H, Rosenberg S, Coffey FJ, et al. A role for cFLIP in B cell proliferation and stress MAPK regulation. J Immunol 2009;182:207–215.
   PubMed Web of Science ®Google Scholar
• Coffey F, Manser T. Expression of cellular FLIP by B cells is required for their participation in an immune response. J Immunol 2010;184:4871–4879.
   PubMed Web of Science ®Google Scholar